Effect of Multiple Dosing With 240 mg BID BI 201335 on the Steady State Pharmacokinetics of 300mg QD Tenofovir and Effect of Multiple Dosing With 300mg QD Tenofovir on Steady State BI 201335 Pharmacokinetics in Healthy Male and Female Volunteers
Phase of Trial: Phase I
Latest Information Update: 04 Aug 2015
At a glance
- Drugs Faldaprevir (Primary) ; Tenofovir (Primary)
- Indications Hepatitis B; HIV infections
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 04 Mar 2013 Results have been presented at the 2013 CROI: Conference on Retroviruses and Opportunistic Infections according to a Boehringer Ingelheim media release.
- 28 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 Jun 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.